Trinidad IM Thyroid Stimulating Hormone (TSH) Assay, Trinidad IM TSH Calibrators, Trinidad Immunoassay (IM) System
Device Facts
| Record ID | K151792 |
|---|---|
| Device Name | Trinidad IM Thyroid Stimulating Hormone (TSH) Assay, Trinidad IM TSH Calibrators, Trinidad Immunoassay (IM) System |
| Applicant | Siemens Healthcare Diagnostics, Inc. |
| Product Code | JLW · Clinical Chemistry |
| Decision Date | Nov 20, 2015 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 862.1690 |
| Device Class | Class 2 |
| Attributes | Pediatric |
Indications for Use
The Trinidad Immunoassay (IM) system is an automated, immunoassay analyzer designed to perform in vitro diagnostic tests on clinical specimens. The Trinidad IM system’s assay application utilizes chemiluminescents technology for clinical use. The Trinidad IM Thyroid Stimulating Hormone (TSH) assay is for in vitro diagnostic use in the quantitative determination of thyroid-stimulating hormone (TSH, thyrotropin) in human serum, and plasma (EDTA and lithium heparin) using the Trinidad IM system. Measurements of the thyroid stimulating hormone produced by the anterior pituitary are used in the diagnosis of thyroid or pituitary disorders. The Trinidad IM TSH Calibrators are for in vitro diagnostic use in calibrating the Trinidad IM system TSH assay.
Device Story
Trinidad IM system is a floor-model, automated, microprocessor-controlled immunoassay analyzer. It processes human serum and plasma samples using chemiluminescent technology. The system aspirates/dispenses samples, performs dilutions, adds reagents, incubates, separates waste, and measures photon emissions via PMT. It uses pre-packaged reagent packs containing paramagnetic particles coated with anti-fluorescein antibody, FITC-labeled anti-TSH capture antibody, and acridinium ester-labeled anti-TSH tracer. The system performs data reduction and maintains patient results. Operated by laboratory personnel in clinical settings. Output is quantitative TSH concentration, aiding clinicians in diagnosing thyroid/pituitary disorders.
Clinical Evidence
Bench testing only. Precision evaluated over 20 days (n=80 replicates per sample) showing CVs < 6%. Linearity confirmed across 0.008–150 µIU/mL (R=1.000). Method comparison against predicate (n=347) yielded y = 1.069x - 0.003 (R=0.994). Interference testing showed no significant impact from hemoglobin, triglycerides, or bilirubin. Cross-reactivity with hCG, FSH, and LH was negligible. LoB 0.001 µIU/mL, LoD 0.005 µIU/mL, and LoQ 0.008 µIU/mL.
Technological Characteristics
Floor-model automated analyzer; chemiluminescent detection using PMT. Reagents: paramagnetic particles (~85 µg/mL), FITC-labeled anti-TSH, acridinium ester-labeled anti-TSH. Sample volume 10-100 µL. Throughput 250-450 tests/hr. Refrigerated reagent storage (4-8°C). Connectivity: LIS interface (ASTM 1394/1381, HL7). Software: Windows 7-based, Intel processor. Power: ~3000 watts.
Indications for Use
Indicated for quantitative determination of TSH in human serum, EDTA plasma, and lithium heparin plasma to aid in the diagnosis of thyroid or pituitary disorders. No specific age or gender restrictions provided.
Regulatory Classification
Identification
A thyroid stimulating hormone test system is a device intended to measure thyroid stimulating hormone, also known as thyrotrophin and thyrotrophic hormone, in serum and plasma. Measurements of thyroid stimulating hormone produced by the anterior pituitary are used in the diagnosis of thyroid or pituitary disorders.
Predicate Devices
- ADVIA® Centaur XP system (K041133)
- ADVIA® Centaur Thyroid Stimulating Hormone (TSH3 Ultra) Assay and Calibrators (K150403)
Related Devices
- K162698 — MAGLUMI 2000 TSH, MAGLUMI 2000 Immunoassay Analyzer · Shenzhen New Industries Biomedical Engineering Co., Ltd. · Jul 14, 2017
Submission Summary (Full Text)
{0}
1
# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY AND INSTRUMENT COMBINATION TEMPLATE
A. 510(k) Number:
k151792
B. Purpose for Submission:
Adding previously cleared assay on a new instrument
C. Measurand:
Thyroid Stimulating Hormone (TSH)
D. Type of Test:
Quantitative, chemiluminescence immunoassay
E. Applicant:
Siemens Healthcare Diagnostics Inc.
F. Proprietary and Established Names:
Trinidad IM Thyroid Stimulating Hormone (TSH) Assay
Trinidad IM TSH Calibrators
Trinidad Immunoassay (IM) System
G. Regulatory Information:
| Product Code | Regulation Name | Classification | Regulation Section | Panel |
| --- | --- | --- | --- | --- |
| JLW | Thyroid stimulating hormone test system | Class II | 21 CFR § 862.1690 | Chemistry 75 |
| JIT | Calibrator, secondary | Class II | 21 CFR§ 862.1150 | Chemistry 75 |
| JJE | Discrete photometric chemistry analyzer for clinical use | Class I | 21 CFR § 862.2160 | Chemistry 75 |
{1}
2
H. Intended Use:
1. Intended use(s):
See indication(s) for use below
2. Indication(s) for use:
The Trinidad Immunoassay (IM) system is an automated, immunoassay analyzer designed to perform in vitro diagnostic tests on clinical specimens. The Trinidad IM system’s assay application utilizes chemiluminescents technology for clinical use.
The Trinidad IM Thyroid Stimulating Hormone (TSH) assay is for in vitro diagnostic use in the quantitative determination of thyroid-stimulating hormone (TSH, thyrotropin) in human serum, and plasma (EDTA and lithium heparin) using the Trinidad IM system. Measurements of the thyroid stimulating hormone produced by the anterior pituitary are used in the diagnosis of thyroid or pituitary disorders.
The Trinidad IM TSH Calibrators are for in vitro diagnostic use in calibrating the Trinidad IM system TSH assay.
3. Special conditions for use statement(s):
For prescription use.
4. Special instrument requirements:
The Trinidad Immunoassay (IM) system
I. Device Description:
The Trinidad Immunoassay (IM) system is an automated, immunoassay analyzer that utilizes chemiluminescent technology. The analyzer is a floor model; fully automated, microprocessor-controlled, integrated instrument system that utilizes chemiluminescent technology and uses pre-packaged reagent packs to measure a variety of analytes in human body fluids.
The Trinidad IM TSH assay Ready Pack consists of the following reagents:
- Lite Reagent: 6.0 mL reagent pack contains bovine serum albumin (BSA) conjugated to murine monoclonal anti-TSH (~0.3 µg/mL) labeled with acridinium ester, buffer, stabilizers (murine, bovine, caprine), surfactant, and preservatives.
- Solid Phase Reagent: 21.0 mL reagent pack contains anti-fluorescein murine monoclonal antibody covalently linked to paramagenetic particles (~85 µg/mL), buffer, stabilizers (bovine, caprine), surfactant, and preservatives.
- Ancillary Reagent: 6.0 mL reagent pack contains fluorescein label (FITC)
{2}
conjugated to murine monoclonal anti-TSH (~0.3 µg/mL), buffer, stabilizers (murine, bovine, caprine), surfactant, and preservatives.
- Wash 3.0 L pack phosphate-buffered saline with sodium azide (<0.1%) and surfactant.
- Trinidad IM TSH calibrator: The Trinidad Calibrators consists of 1 (2mL) vial of lyophilized low calibrator and 1 (2mL) vial of lyophilized high calibrator. After reconstitution, the calibrators contain low and high levels of TSH, buffer, equine serum, sodium azide (0.1%), and preservatives. The low and high calibrators are targeted at ~0.032 and 97.5 µIU/mL.
The Trinidad IM TSH reagents and Trinidad IM TSH calibrator are the same reagents and calibrators as the reagents and calibrators cleared in the predicate device (k150403). The packaging is identical and the only difference is the labeling.
J. Substantial Equivalence Information:
1. Predicate device name(s):
ADVIA Centaur Thyroid Stimulating Hormone (TSH) assay, including calibrators
ADVIA Centaur XP system
2. Predicate 510(k) number(s):
k150403, k041133
3. Comparison with predicate:
Instrument
| Similarities and Differences | | |
| --- | --- | --- |
| Item | Candidate Device
Trinidad IM System | Predicate Device
Advia Centaur XP system
k041133 |
| Intended Use | An automated immunoassay analyzer designed to perform in vitro diagnostic immunochemical assay analysis on clinical specimens | Same |
| Type of system | Random access and batch | Same |
| Throughput rate | 250 to 450 tests/hour | 120 to 240 tests/hour |
| External connectivity to LIS | Yes | Same |
| Sample container | sample cups or primary tubes | Same |
{3}
| Similarities and Differences | | |
| --- | --- | --- |
| Item | Candidate Device Trinidad IM System | Predicate Device Advia Centaur XP system k041133 |
| | | |
| Dispense system | Automated pipetting of samples using precision syringe | Same |
| Sample probe | Air pressure fluid sensing and disposable tip sensing; clog detection mechanism to alert operator to clogged sample probe. | Same |
| Sample size | 10 to 100 μL | 10 to 200 μL |
| Dilutions | Allowed on per-assay basis; capability of dilution of samples requiring pretreatment | Same |
| Reagent storage temp. | 4 °C to 8 °C | Same |
TSH Assay Reagent
| Similarities and Differences | | |
| --- | --- | --- |
| Item | Candidate Device Trinidad IM Thyroid Stimulating Hormone (TSH) Assay | Predicate Device Advia Centaur TSH assay k150403 |
| Intended Use | For in vitro diagnostic use in the quantitative determination of thyroid stimulating hormone (TSH, thyrotropin) in serum, heparinized plasma, and EDTA plasma | Same |
| Measured analyte | thyroid stimulating hormone (TSH) also known as thyrotropin | Same |
| Principle of assay | Chemiluminescence using magnetic particle solid phase and chemiluminescents label | Same |
{4}
| Similarities and Differences | | |
| --- | --- | --- |
| Item | Candidate Device Trinidad IM Thyroid Stimulating Hormone (TSH) Assay | Predicate Device Advia Centaur TSH assay k150403 |
| Analytical measuring range | 0.008-150 μIU/mL | Same |
| Sample type | serum, heparinized plasma, and EDTA plasma | Same |
TSH Calibrator
| Similarities and Differences | | |
| --- | --- | --- |
| Item | Candidate Device Trinidad IM Thyroid Stimulating Hormone (TSH) Calibrator | Predicate Device Advia Centaur TSH Calibrator k150403 |
| Intended Use | In vitro diagnostic use in calibrating the TSH assay. | Same |
| Calibration | Two-point user run calibration | Same |
| Matrix | Lyophilized buffered equine serum | Same |
| Traceability | Standardized to internal standards and is traceable to the WHO 3rdInternational standard for human TSH (IRP 81/565) | Same |
# K. Standard/Guidance Document Referenced (if applicable):
CLSI EP05-A3: Evaluation of Precision of Qualitative Measurement Methods Procedures; Approved Guideline
CLSI Guideline EP17-A2: Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline
CLSI Guideline EP28-A3c: Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline- Third Edition
CLSI Guideline EP7-A2: Interference Testing in Clinical Chemistry; Approved Guideline
{5}
6
L. Test Principle:
The Trinidad IM TSH assay employs anti-FITC monoclonal antibody covalently bound to paramagnetic particles, a FITC-labeled anti-TSH capture monoclonal antibody, and a tracer consisting of a proprietary acridinum ester and an anti-TSH monoclonal antibody conjugated to bovine serum albumin (BSA) for chemiluminescents detection.
A direct relationship exists between the amount of TSH present in the patient sample and the amount of relative light units (RLUs) detected by the system.
M. Performance Characteristics (if/when applicable):
1. Analytical performance:
a. Precision/Reproducibility:
Precision was performed on 20 days on 2 Trinidad IM systems with 2 reagent lots in accordance with CLSI EP05-A2 as a guideline. Repeatability and within-lab imprecision was evaluated by testing four serum-based controls, six human serum pools and six human plasma pools (three EDTA and three lithium heparin). The samples were run in 2 replicates per run, 2 runs per day for 20 days for a total of 80 replicates. The following precision results were obtained:
| Specimen Type | Mean (μIU/mL) | Repeatability | | Within-Lab | |
| --- | --- | --- | --- | --- | --- |
| | | SD (μIU/mL) | CV (%) | SD (μIU/mL) | CV (%) |
| Control 1 | 0.034 | 0.001 | 2.356 | 0.002 | 4.448 |
| Control 2 | 0.404 | 0.008 | 1.956 | 0.017 | 4.205 |
| Control 3 | 5.257 | 0.091 | 1.735 | 0.233 | 4.439 |
| Control 4 | 32.826 | 0.599 | 1.824 | 1.624 | 4.946 |
| Plasma Pool 1 | 3.378 | 0.079 | 2.345 | 0.152 | 4.448 |
| Plasma Pool 2 | 37.894 | 1.258 | 3.321 | 2.253 | 5.947 |
| Plasma Pool 3 | 143.658 | 3.681 | 2.562 | 7.671 | 5.339 |
| Plasma Pool 4 | 0.724 | 0.010 | 1.448 | 0.029 | 4.003 |
| Plasma Pool 5 | 4.992 | 0.106 | 2.119 | 0.209 | 4.194 |
| Plasma Pool 6 | 79.946 | 1.792 | 2.241 | 3.855 | 4.822 |
| Serum Pool 1 | 1.106 | 0.016 | 1.459 | 0.041 | 3.665 |
| Serum Pool 2 | 5.827 | 0.086 | 1.474 | 0.242 | 4.150 |
| Serum Pool 3 | 11.440 | 0.213 | 1.858 | 0.425 | 3.713 |
| Serum Pool 4 | 34.709 | 0.626 | 1.804 | 1.247 | 3.592 |
| Serum Pool 5 | 59.879 | 1.056 | 1.764 | 2.266 | 3.784 |
| Serum Pool 6 | 131.895 | 2.657 | 2.014 | 6.226 | 4.720 |
{6}
b. Linearity/assay reportable range:
The Trinidad IM TSH linearity was evaluated by using a high TSH serum sample (151.4 µIU/mL) mixed with a low equine serum pool (0.001 µIU/mL) to prepare intermixed samples ranging in various different TSH levels. All nine samples were assayed in triplicate using one reagent lot on one Trinidad IM system.
The weighted Deming regression equation is:
$$
y = 0.957x + 0.0000; R = 1.000
$$
The sponsor claimed that the TSH assay has a measuring range of 0.008 to 150 µIU/L.
c. Traceability, Stability, Expected values (controls, calibrators, or methods):
The Trinidad IM TSH assay is standardized to internal standards, which are traceable to the World Health Organization (WHO) 3rd International Standard for Human TSH (IRP 81/565).
The Trinidad IM Thyroid Stimulating Hormone (TSH) assay utilizes a factory set master curve standards (10 levels) that have fixed TSH doses and corresponding relative light units (RLU) signals that are reagent dependent. The master curve values are contained on the master curve card provided with each kit. The barcode reader or keyboard is used to enter the master curve values on the system. The 2 calibrators in the kit are run when the lot is first used or after expiration of the calibration interval. If the calibration run is valid as determined by prearranged parameters, the values are stored and used to "normalize" test values to the master curve.
The sponsor has a statement in the package insert: Do not mix calibrator lots with different lots of reagent packs.
The Trinidad IM TSH calibrators were previously cleared under k041133.
Trinidad IM Thyroid Stimulating Hormone (TSH) Calibrators are stable at 2-8 °C for 12 months unopened. The open vial stability (reconstituted) is stable for 28 days and the on-system stability is 4 hours. The stability study protocol and acceptance criteria have been provided and found to be adequate.
d. Detection limit:
The Limit of Blank (LoB) for the Trinidad IM TSH assay was determined as recommended in CLSI guideline EP17-A2 (Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures). Five blank samples with no detectable
7
{7}
levels of TSH were assayed for a minimum of two runs per day, two replicates per run, using three lots of reagent on two Trinidad IM systems over five days for a total of 200 replicates. The LoB was established as the TSH value corresponding to the $95^{\text{th}}$ rank position in each dataset. LoB was calculated to be $0.001 \mu \mathrm{IU} / \mathrm{mL}$ .
The Limit of Detection (LoD) was determined as recommended in CLSI guideline EP17-A2 by using five serum samples with TSH levels ranging from 0 to 0.0073 $\mu \mathrm{IU} / \mathrm{mL}$ . All samples were assayed in duplicate in each of a minimum of 20 runs using three lots of reagents on two Trinidad IM systems over a minimum of 10 days $(n = 80)$ . The LoD was calculated to be $0.005\mu \mathrm{IU} / \mathrm{mL}$ using the following equation $\mathrm{LoD} = \mathrm{LoB} + \mathrm{c_pSD_L}$ .
The Limit of Quantitation (LoQ), using functional sensitivity, was determined by using five (5) low-level TSH serum sample. TSH levels ranging from 0.0078 to $0.0208\mu \mathrm{IU} / \mathrm{mL}$ were used. All samples were assayed in duplicate in each of 10 runs, on two Trinidad IM systems, using three reagent lots, and over a period of at least 10 days $(n = 80)$ .
The functional sensitivity was based on the within lab precision of $20\%$ CV and was determined to be $0.008~\mu \mathrm{IU / mL}$ .
The claimed measuring range of the assay is 0.008 to $150~\mu \mathrm{IU / mL}$
# e. Analytical specificity:
An interference study was conducted to evaluate the effect of endogenous interfering substances (hemoglobin, triglycerides, bilirubin, conjugated and unconjugated) using 4 serum samples on the Trinidad IM TSH assay. All samples were tested in triplicate with one reagent lot on one Trinidad IM system. Based on the sponsors definition of non-significant interference ( $\leq 10\%$ recovery of the control value), no significant interference for the substances and concentrations listed below:
| Potential interfering endogenous substances | Highest interferent concentration tested at which no significant interference was observed |
| --- | --- |
| Hemoglobin | 600 mg/dL |
| Triglycerides (Intralipid) | 2000 mg/dL |
| Bilirubin, conjugated | 60 mg/dL |
| Bilirubin, unconjugated | 60 mg/dL |
In addition, to determine the cross reactivity of related proteins in the Trinidad TSH assay, four human samples with TSH levels of 0.37, 3.74-3.83, 44.1-45.8 and 120-125 $\mu$ IU/mL were spiked with the following levels of cross-reactants:
{8}
hCG at 200,000 µIU/mL
FSH at 1500 µIU/mL
LH at 600 µIU/mL
The control samples and the spiked samples were assayed in triplicate using one reagent lot on one Trinidad IM system.
Based on the sponsor’s definition of non-significant interference (≤5% of the control value), no significant interference for the compounds and concentrations below:
| Compound Tested | Concentration |
| --- | --- |
| hCG | 200,000 µIU/mL |
| FSH | 1500 µIU/mL |
| LH | 600 µIU/mL |
Hook effect: To evaluate the potential for high dose hook effect in the Trinidad IM TSH assay a high TSH sample (~9200 µIU/mL) was prepared. The sample was serially diluted 2-fold. The neat sample and the dilutions were assayed in triplicate with one lot of reagent on one Trinidad IM system. There was no high dose effect observed at TSH concentrations up to 3,000 µIU/mL.
The sponsor included the following statement in the Trinidad IM TSH assay package insert:
“High TSH levels can cause a paradoxical decrease in the RLUs (high-dose hook effect). In this assay, TSH levels as high as 3000 µIU/mL (mIU/L) will assay greater than 150 µIU/mL.”
f. Assay cut-off:
Not applicable)
2. Comparison studies:
a. Method comparison with predicate device:
A method comparison study was performed to compare TSH on the Trinidad IM TSH assay with the Advia Centaur TSH3-Ultra assay (predicate). A total of 347 samples ranging from 0.008-148.8 µIU/mL were tested. A total of 24 samples were contrived (7% contrived). Samples were assayed in duplicate using one reagent lot on two Trinidad IM systems and one Advia Centaur XP system. Testing was performed over multiple days. Deming regression analysis was performed using the first replicate of each data set. The data is summarized in the table below:
{9}
| n | Weighted Deming Regression | Correlation Coefficient | Sample Range (μIU/mL) |
| --- | --- | --- | --- |
| 347 | y = 1.069x - 0.003 | 0.994 | 0.008 – 148.787 |
# b. Matrix comparison:
A matrix comparison study was conducted utilizing ninety matched lithium heparin, EDTA plasma and serum samples. Seven sets were spiked with TSH to cover the upper range of the assay. The TSH values ranged from 0.014 to $135\mu \mathrm{IU} / \mathrm{mL}$ . All samples were assayed in duplicate with one reagent lot on one Trinidad IM system. The statistical results using the Deming regression was performed on plasma verses serum samples. The first replicate of each data set was used for the analysis. Results are summarized in the table below:
| Sample | n | Weighted Deming Regression | Correlation Coefficient | Sample range (μIU/mL) |
| --- | --- | --- | --- | --- |
| Lithium Heparin | 90 | 1.01x – 0.001 | 0.999 | 0.014-134.530 |
| EDTA Plasma | 90 | 1.00x – 0.0001 | 1.000 | 0.014-134.530 |
# 3. Clinical studies:
a. Clinical Sensitivity:
Not applicable
b. Clinical specificity:
Not applicable
c. Other clinical supportive data (when a. and b. are not applicable):
Not applicable
# 4. Clinical cut-off:
Not applicable
# 5. Expected values/Reference range:
The reference interval was previously established on the Advia Centaur System using the predicate device (in k0150403); including the pediatric reference intervals. To verify the reference range, a transferability and verification study was conducted according to CLSI
{10}
Guideline EP28-A3c. The study results support the original reference range established with the predicate device. The expected values are as follows:
| Age Range | Reference Range |
| --- | --- |
| Infants (01 – 23 months) | 0.87 – 6.15 μIU/mL |
| Children (02 – 12 years) | 0.67 – 4.16 μIU/mL |
| Adolescents (13-20 years) | 0.48 – 4.17 μIU/mL |
| Adults (≥ 21 years) | 0.55 – 4.78 μIU/mL |
# N. Instrument Name:
Trinidad Immunoassay (IM) System
# O. System Descriptions:
1. Modes of Operation:
Does the applicant's device contain the ability to transmit data to a computer, webserver, or mobile device?
Yes X or No
Does the applicant's device transmit data to a computer, webserver, or mobile device using wireless transmission?
Yes or No X
2. Software:
FDA has reviewed applicant's Hazard Analysis and software development processes for this line of product types:
Yes X or No
3. Specimen Identification:
Manual entry, Barcode, or LIS
4. Specimen Sampling and Handling:
Automated or manual sample dilution, automated sample handling
5. Calibration:
The Trinidad IM TSH Calibrators are provided with each kit. Calibration is required at
{11}
the end of the 14-day pack calibration interval, for calibrated reagent packs on the system.
6. Quality Control:
The sponsor recommends analyzing two levels of quality control material with a known TSH concentration at least once each day.
P. Other Supportive Instrument Performance Characteristics Data Not Covered In The "Performance Characteristics" Section above:
A carry over study has been performed and found to be acceptable.
Q. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.
R. Conclusion:
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.
12
